|Bid||2.50 x 5000|
|Ask||2.68 x 300|
|Day's Range||2.87 - 3.22|
|52 Week Range||0.67 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2017 - Mar 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of David M. Kendall, MD, as Chief Medical Officer, effective February 12. Dr. Kendall will assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity.
WESTLAKE VILLAGE, Calif., Feb. 06, 2018-- MannKind Corporation today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind’ ...
Nate Pile's position in Nvidia appreciated 74% last year making his weighting in semiconductor stocks uncomfortably large. Recently, Nate trimmed his position in Nvidia and bought more MannKind, Apple, and Celgene.
NEW YORK, NY / ACCESSWIRE / January 26, 2018 / Strong earnings from major companies such as 3M and Boeing helped lift the Dow and S&P 500 to new record highs on Thursday. The Dow Jones Industrial Average ...
WESTLAKE VILLAGE, Calif., Jan. 16, 2018-- MannKind Corporation, focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary ...
Last year, prospects for Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) looked promising, until markets grew risk-adverse for small-cap biotechnology companies. Are bears right in betting against Synergy stock? Bears are sitting on gains with their 30.5% short float position in SGYP stock.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
MannKind hasn’t been making great leaps in recent years. MannKind (MNKD) shares collapsed 72% in 2015 and followed that with a 56% tumble in 2016. MannKind, which focuses on inhaled therapies for diabetes and pulmonary arterial hypertension, has had personnel issues, as well.
NEW YORK, Nov. 29, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microsoft ...